JP2021513519A5 - - Google Patents
Info
- Publication number
- JP2021513519A5 JP2021513519A5 JP2020541908A JP2020541908A JP2021513519A5 JP 2021513519 A5 JP2021513519 A5 JP 2021513519A5 JP 2020541908 A JP2020541908 A JP 2020541908A JP 2020541908 A JP2020541908 A JP 2020541908A JP 2021513519 A5 JP2021513519 A5 JP 2021513519A5
- Authority
- JP
- Japan
- Prior art keywords
- azabicyclo
- hexane
- amine
- pyridazin
- pharmaceutically acceptable
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862625656P | 2018-02-02 | 2018-02-02 | |
| US62/625,656 | 2018-02-02 | ||
| PCT/US2019/016300 WO2019152809A1 (en) | 2018-02-02 | 2019-02-01 | Antagonists of the muscarinic acetylcholine receptor m4 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021513519A JP2021513519A (ja) | 2021-05-27 |
| JP2021513519A5 true JP2021513519A5 (https=) | 2022-02-16 |
| JPWO2019152809A5 JPWO2019152809A5 (https=) | 2022-02-16 |
| JP7352294B2 JP7352294B2 (ja) | 2023-09-28 |
Family
ID=67480022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541908A Active JP7352294B2 (ja) | 2018-02-02 | 2019-02-01 | ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11414406B2 (https=) |
| EP (1) | EP3746421B1 (https=) |
| JP (1) | JP7352294B2 (https=) |
| KR (1) | KR20200116945A (https=) |
| CN (1) | CN111788182B (https=) |
| AU (1) | AU2019216492A1 (https=) |
| CA (1) | CA3090130A1 (https=) |
| IL (1) | IL276411B2 (https=) |
| WO (1) | WO2019152809A1 (https=) |
| ZA (1) | ZA202004638B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12600726B2 (en) | 2017-07-12 | 2026-04-14 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| IL310346A (en) | 2017-10-20 | 2024-03-01 | Univ Vanderbilt | Muscarinic acetylcholine M4 receptor antagonists |
| EP3728228A1 (en) | 2017-12-22 | 2020-10-28 | Ravenna Pharmaceuticals, Inc. | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| WO2020243423A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| KR20220030222A (ko) | 2019-05-31 | 2022-03-10 | 이케나 온콜로지, 인코포레이티드 | Tead 억제제 및 이의 용도 |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| AU2020358000A1 (en) * | 2019-10-04 | 2022-04-07 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| WO2021174176A1 (en) * | 2020-02-28 | 2021-09-02 | Remix Therapeutics Inc. | Pyridazine dervatives for modulating nucleic acid splicing |
| IL303128A (en) | 2020-11-26 | 2023-07-01 | Rezubio Pharmaceuticals Co Ltd | Anticholinergic agents |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2676444B1 (fr) * | 1991-05-16 | 1995-03-10 | Sanofi Elf | Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant. |
| EP2280003B1 (en) | 2002-07-15 | 2014-04-02 | Symphony Evolution, Inc. | Process for preparing receptor-type kinase modulators |
| US20040044029A1 (en) | 2002-08-14 | 2004-03-04 | Dart Michael J. | Azabicyclic compounds are central nervous system active agents |
| EP1581522B1 (en) * | 2002-12-23 | 2008-02-20 | Ranbaxy Laboratories Limited | Flavaxate derivatives as muscarinic receptor antagonists |
| WO2004089898A1 (en) * | 2003-04-09 | 2004-10-21 | Ranbaxy Laboratories Limited | Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists |
| PT2213661E (pt) | 2003-09-26 | 2011-12-15 | Exelixis Inc | Moduladores de c-met e métodos de uso |
| DE102004039789A1 (de) | 2004-08-16 | 2006-03-02 | Sanofi-Aventis Deutschland Gmbh | Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP1796667A2 (en) * | 2004-09-27 | 2007-06-20 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| WO2006035280A1 (en) * | 2004-09-27 | 2006-04-06 | Ranbaxy Laboratories Limited | 3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| EP1904495A2 (en) * | 2005-07-11 | 2008-04-02 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
| GB0521508D0 (en) * | 2005-10-21 | 2005-11-30 | Novartis Ag | Organic compounds |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| WO2008065500A2 (en) | 2006-11-30 | 2008-06-05 | Pfizer Products Inc. | Heteroaryl amides as type i glycine transport inhibitors |
| EP2129660A2 (en) * | 2006-12-19 | 2009-12-09 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| CN101230058A (zh) | 2007-01-23 | 2008-07-30 | 上海恒瑞医药有限公司 | 双环氮杂烷类衍生物、其制备方法及其在医药上的用途 |
| CN103102352B (zh) | 2011-11-15 | 2015-08-12 | 山东亨利医药科技有限责任公司 | 酪氨酸激酶抑制剂吲哚满酮衍生物 |
| AU2014224975B2 (en) * | 2013-03-05 | 2017-09-14 | Merck Patent Gmbh | Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer |
| TW201444820A (zh) | 2013-03-13 | 2014-12-01 | Abbvie Inc | 吡啶ｃｄｋ９激酶抑制劑 |
| MA39838B1 (fr) | 2014-04-04 | 2019-05-31 | Pfizer | Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4 |
| PE20211782A1 (es) | 2014-05-23 | 2021-09-08 | Hoffmann La Roche | Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos |
| JO3579B1 (ar) | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| EP3371164B1 (en) | 2015-11-06 | 2022-03-16 | Neurocrine Biosciences, Inc. | N-[2-(1-benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases |
| EA201800367A1 (ru) * | 2015-12-10 | 2019-02-28 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы лечения болезни хантингтона |
| KR20180110132A (ko) | 2016-02-16 | 2018-10-08 | 반더빌트유니버시티 | 무스카린성 아세틸콜린 수용체 m1의 양성 알로스테릭 조절제 |
| US20170355708A1 (en) * | 2016-06-09 | 2017-12-14 | Cadent Therapeutics, Inc. | Potassium channel modulators |
| AU2018313802A1 (en) * | 2017-08-08 | 2020-02-20 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| WO2019079410A1 (en) * | 2017-10-17 | 2019-04-25 | Vanderbilt University | ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4 |
| IL310346A (en) | 2017-10-20 | 2024-03-01 | Univ Vanderbilt | Muscarinic acetylcholine M4 receptor antagonists |
| AU2018360581A1 (en) | 2017-10-31 | 2020-06-11 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| EP3732163A4 (en) * | 2017-12-20 | 2021-07-14 | Vanderbilt University | MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS |
-
2019
- 2019-02-01 CN CN201980012827.5A patent/CN111788182B/zh not_active Expired - Fee Related
- 2019-02-01 JP JP2020541908A patent/JP7352294B2/ja active Active
- 2019-02-01 WO PCT/US2019/016300 patent/WO2019152809A1/en not_active Ceased
- 2019-02-01 KR KR1020207023725A patent/KR20200116945A/ko not_active Ceased
- 2019-02-01 EP EP19747509.8A patent/EP3746421B1/en active Active
- 2019-02-01 US US16/966,306 patent/US11414406B2/en active Active
- 2019-02-01 IL IL276411A patent/IL276411B2/en unknown
- 2019-02-01 AU AU2019216492A patent/AU2019216492A1/en not_active Abandoned
- 2019-02-01 CA CA3090130A patent/CA3090130A1/en active Pending
-
2020
- 2020-07-27 ZA ZA2020/04638A patent/ZA202004638B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513519A5 (https=) | ||
| TWI579284B (zh) | 咪唑并吡咯啶酮化合物 | |
| AU2019283921A1 (en) | Indole carboxamide compounds useful as kinase inhibitors | |
| TW444013B (en) | Quinoline and quinazoline compounds useful in treating benign prostatic hyperplasia | |
| JP2021500345A5 (https=) | ||
| IL273924B2 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| RU2009136299A (ru) | Новые производные 3-({1,2,4}триазоло{4,3-а}пиридин-7-ил)бензамида | |
| JP2017533968A5 (https=) | ||
| JP2009538910A5 (https=) | ||
| CA2883894A1 (en) | Compounds and methods for kinase modulation, and indications therefor | |
| WO2003000657A1 (en) | Diamine derivatives | |
| JPH0219112B2 (https=) | ||
| JP2001524116A (ja) | ５ｈｔ１ａ、５ｈｔ１ｂおよび５ｈｔ１ｄ受容体アンタゴニスト活性を合わせ持つインドール誘導体 | |
| CN107108588A (zh) | 可用于治疗癌症的稠合双环(杂)芳香族化合物 | |
| CN104125947A (zh) | 杂环脲化合物 | |
| CN105189497B (zh) | 作为janus激酶抑制剂的n-(2-氰基杂环基)吡唑并吡啶酮 | |
| WO2022140769A1 (en) | Lactam (hetero)arylfusedpyrimidine derivatives as inhibitors of erbb2 | |
| JP2019537581A5 (https=) | ||
| AU2021299200A1 (en) | Processes for making SERD tricyclic compounds having a substituted phenyl or pyridinyl moiety | |
| JPWO2019152809A5 (https=) | ||
| JP2020503295A5 (https=) | ||
| JP7168245B2 (ja) | 三環式化合物 | |
| AU2015212495A1 (en) | Antibacterial combinations comprising polymyxin | |
| JPWO2021050824A5 (https=) | ||
| WO2016039448A1 (ja) | 芳香族カルボン酸アミド化合物 |